...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current Opinion in Molecular Therapeutics >New molecular assays for cancer diagnosis and targeted therapy.
【24h】

New molecular assays for cancer diagnosis and targeted therapy.

机译：用于癌症诊断和靶向治疗的新分子检测。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Microarray multiplex protein measurement of biomarker-based molecular diagnostic and prognostic cancer testing assays is destined to become a large growth segment of the immunodiagnostic industry. Assays encompass immunohistochemistry, fluorescence in situ hybridization, ELISA and sequencing methods that must comply with stringent regulatory specifications. Current test services available range from single-site service-based assays to multi-laboratory testing. Some tests have regulatory approval, whereas others are regulated by the Clinical Laboratory Improvement Act or the College of American Pathologists, or both. Expectations of personalized medicine are building, and the future is expected to bring truly targeted treatments based on test results. In this review, biomarkers, screening, diagnosis, potential prognosis and treatment pertaining to colorectal, breast, and lung cancers are discussed and evaluated. Assay data are expected to improve clinical indices and treatment algorithms, leading to dynamic disease models for real-time, data-modulated patient management.
机译：基于生物标志物的分子诊断和预后癌症测试分析的微阵列多重蛋白测量注定将成为免疫诊断行业的一大增长领域。分析包括免疫组织化学，荧光原位杂交，ELISA和测序方法，这些方法必须符合严格的法规要求。当前可用的测试服务范围从基于单站点服务的分析到多实验室测试。有些测试获得监管部门的批准，而另一些则受《临床实验室改进法》或美国病理学家学院（或两者兼有）的监管。个性化医学的期望正在建立，并且未来有望根据测试结果带来真正针对性的治疗。在这篇综述中，讨论并评估了与大肠癌，乳腺癌和肺癌有关的生物标志物，筛查，诊断，潜在的预后和治疗。分析数据有望改善临床指标和治疗算法，从而为实时，数据调制的患者管理提供动态疾病模型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号